Metformin

Generic Name
Metformin
Brand Names
Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
Drug Type
Small Molecule
Chemical Formula
C4H11N5
CAS Number
657-24-9
Unique Ingredient Identifier
9100L32L2N
Background

Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...

Indication

Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)
...

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
-
Clinical Trials
Related News
springermedizin.de
·

Different Models, Same Results: Considerations When Choosing Between Approaches to Assess Cost-Effectiveness of CAR-T Therapies

Article compares three modelling approaches (PSM, DES, STM) for assessing cost-effectiveness of CAR-T therapies in young patients with r/r ALL, finding minor variations in results due to different modelling approaches, with DES generating the most LYs and QALYs for tisagenlecleucel. Sensitivity analysis shows cost-effectiveness most impacted by cure-point assumption, duration of IVIg use, and CAR-T wait time, with DES being the only structure allowing for wait time testing. Checklist developed to summarize criteria captured by each model type, emphasizing DES's ability to incorporate complex treatment pathways and individual patient history.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy